Feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya

• Published in: BMC public health Vol. 22; no. 1; pp. 2385 - 12
• Main Authors: Mutisya, Elizabeth Mueni, Muturi-Kioi, Vincent, Abaasa, Andrew, Nyasani, Delvin, Kabuti, Rhoda W, Lunani, Laura, Kotikot, Timothy, Mundia, Moses, Mutua, Gaudensia, Ombati, Geoffrey, Nduta, Hannah, Price, Matt A, Kimani, Joshua, Anzala, Aggrey Omu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.12.2022; BioMed Central; BMC
• Subjects: Clinical trials; Feasibility; Feasibility Studies; Female; HIV Infections - epidemiology; HIV prevention; Homosexuality, Male; Humans; Kenya; Kenya - epidemiology; Key population; Male; Sex Workers; Sexual and Gender Minorities; Kenya; Clinical trials; Key population; Feasibility; HIV prevention; Kenya
• DOI: 10.1186/s12889-022-14875-2
• ISSN: 1471-2458

To assess the feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya. HIV prevention trials require the inclusion of those at high risk of HIV infection and their informed decision to take part and remain in the clinical trial to the end is crucial. In Kenya key populations including men who have sex with men (MSM) and female sex workers (FSW) are, disproportionately, at high risk of HIV infection when compared to the general population. Few trials testing biomedical prevention products against HIV have enrolled Kenyan FSW and MSM. We performed simulated vaccine efficacy trial (SiVET) using licensed hepatitis B vaccines as substitutes for a HIV vaccine candidate and included randomization for those immune to hep B. The SiVET was an observational study designed to mimic the rigors of a clinical trial; we assessed HIV risk, provided risk counselling and prevention tools and performed HIV testing at baseline and periodically until the end of the trial. MSM and FSW were enrolled at a ratio of 4:1. Volunteers were assigned to either hepatitis B vaccine or placebo. Recruitment took approximately 24 months between Sep 2015 and Sep 2017. Of the 368 volunteers screened, 250 (200 MSM and 50 FSW) were enrolled. Reasons for exclusion at screening included: being positive for HIV (n = 7), hepatitis (n = 14), other pre-existing medical conditions (n = 41), eligible but chose not to enrol (n = 47). Most of the volunteers adhered to study procedures and attended their study visits within the study window. These include volunteers who received the second vaccination 244 (98%), the third vaccination 228 (91%) and, the final study visit 217 (87%). The reasons volunteers discontinued from the study early included: relocation and loss to follow up (n = 14). A total of 8 cases of HIV infection were observed in 174.5 Person Years at Risk (PYAR), all among MSM, including 5 seroconversions identified at the last study visit, for a HIV incidence of 4.58 cases/ 100 PYAR, among MSM enrolled in the study. Our findings suggest that it is possible to conduct HIV prevention trials among key populations in Nairobi with a good adherence to a vaccine efficacy trial schedule. Despite HIV prevention efforts, we also noted a high incidence of HIV infection. This demonstrates the need for effective HIV prevention products in these populations.